Skip to main content

Health condition

Nephrogenic systemic fibrosis, a rare gadolinium-linked condition that is now largely preventable.

Skin and connective tissue thickening tied to certain MRI contrast agents in people with severe kidney impairment - understanding the risk, and how it's managed today.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Editorial team

    Written by our editorial team from the UK sources listed on each page.

  • 02

    Sourced from guidance

    Checked against MHRA, Royal College of Radiologists and peer-reviewed sources you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK gadolinium safety protocols and renal screening practice before MRI contrast.

Key facts

Nephrogenic systemic fibrosis at a glance.

The essentials, in plain English - who it affects, why it happens and how it's approached in the UK today.

  • What it is

    A rare but serious fibrosing disorder of skin and connective tissue linked to gadolinium-based contrast exposure in patients with severe kidney impairment.

  • Who is at risk

    Almost exclusively patients with an eGFR under 30, acute kidney injury, or those on dialysis at the time of a gadolinium-enhanced MRI scan.

  • Onset

    Symptoms usually appear days to months after exposure - occasionally longer in rare cases.

  • Prevention

    Now largely preventable - UK and EU protocols restrict high-risk agents in patients with reduced kidney function.

  • Cure

    There is no definitive cure - management is supportive, focused on mobility, pain and any residual kidney impairment.

  • Rarity today

    New cases are now very uncommon since safer agents and screening became routine practice from around 2007 onwards.

Why this guide matters

A rare condition, but one worth understanding.

Nephrogenic systemic fibrosis is uncommon today, but the reasons why matter for anyone with reduced kidney function facing an MRI scan.

  • Kidney function is the key variable

    Risk is concentrated almost entirely in people with severe kidney impairment - not the general MRI population.

  • Prevention has changed the picture

    Safer agents, lower doses and pre-scan screening have made new cases genuinely rare since protocols tightened.

  • Early recognition still matters

    For anyone affected, prompt referral to dermatology and nephrology gives the best chance of limiting progression.

How the diagnosis is made

From suspicion to a confirmed diagnosis.

The steps a UK dermatology or nephrology team will normally follow, in order - so you know what to expect and why.

  1. 01

    Assessing

    Clinical history and exposure check

    A careful history looking for any gadolinium-enhanced MRI scan in the preceding months, alongside known kidney disease.

  2. 02

    Assessing

    Skin and joint examination

    Assessing the pattern, extent and texture of skin thickening, and any limitation in joint movement.

  3. 03

    Assessing

    Renal function review

    Checking eGFR both currently and, where records allow, at the time of the gadolinium exposure itself.

  4. 04

    Confirming

    Skin biopsy

    Histological confirmation is the gold standard - looking for the characteristic fibrosing changes in the dermis.

  5. 05

    Confirming

    Excluding other fibrosing conditions

    Ruling out scleroderma, morphea and eosinophilic fasciitis, which can look similar clinically.

  6. 06

    Planning

    Dermatology and nephrology referral

    A joint specialist opinion to confirm diagnosis and plan supportive, multidisciplinary care.

  7. 07

    Planning

    Ongoing monitoring

    Tracking skin changes, mobility and any internal organ involvement, plus reviewing kidney function over time.

Typical timeline: from first suspicion to a confirmed plan, usually within a few weeks.

Symptoms

What nephrogenic systemic fibrosis looks like.

Skin thickening that spreads and stiffens joints - and the features that mean it's time to escalate.

  • Skin thickening

    Symmetrical hardening of the skin, typically starting in the lower legs and arms and spreading over weeks.

  • Woody, tight skin texture

    Affected skin can feel firm and board-like, often described by patients as woody or peau d’orange.

  • Reduced joint mobility

    Tightening around joints such as knees, ankles, elbows and wrists can restrict movement and flexion.

  • Pain and burning

    Affected areas can be tender, itchy or burning, particularly in the earlier stages of the condition.

  • Internal organ involvement

    In severe cases fibrosis can extend to the lungs, heart, diaphragm and skeletal muscle.

  • Plaques and papules

    Reddened or darkened patches and small nodules can appear alongside the areas of thickening.

  • Delayed onset

    Symptoms can emerge days after the scan, or sometimes not until weeks or months later.

  • Red flag - rapid spread or breathlessness

    Fast-spreading skin change or new breathlessness needs urgent specialist assessment.

Treatment

How it's managed in the UK.

There is no definitive cure, so care focuses on mobility, comfort and preventing further exposure - with specialist-commissioned options for severe disease.

  • Physiotherapy

    Regular, structured exercise and stretching to maintain joint mobility and slow contracture progression.

  • Pain management

    A stepped approach to analgesia for the pain, burning and itching that affected skin can cause.

  • Treating residual kidney disease

    Optimising any ongoing renal impairment, including dialysis review where relevant, under nephrology.

  • Avoiding further gadolinium

    Lifelong avoidance of high-risk gadolinium agents, with any future imaging carefully risk-assessed.

  • Extracorporeal photopheresis

    A specialist-commissioned option with reported benefit in some severe cases, delivered in tertiary centres.

  • Other specialist therapies

    Occasional reports of benefit from treatments such as UVA1 phototherapy or plasmapheresis in resistant disease.

  • Improving kidney transplant status

    Where appropriate, progressing towards transplantation can improve renal function and may help stabilise disease.

  • Multidisciplinary specialist care

    Dermatology, nephrology and radiology working together is standard for confirmed or suspected cases.

What this guide is based on

The sources behind every claim on this page.

UK regulatory guidance and specialist society standards, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your radiologist, nephrologist or dermatologist knows your history and can tell you which parts apply to you. If in doubt, get seen.

  • MHRA. Gadolinium-containing contrast agents - safety update and restrictions.

  • Royal College of Radiologists. Standards for the use of gadolinium-based contrast agents.

  • European Medicines Agency (EMA). PRAC review of gadolinium contrast agents and nephrogenic systemic fibrosis.

  • British Association of Dermatologists. Guidance on fibrosing skin conditions.

Red flags

When it needs urgent attention.

Most concerns can be managed with routine specialist follow-up. These are the situations that need faster action.

  • Rapidly progressive skin thickening

    Fast-spreading hardening of the skin over days rather than weeks warrants urgent specialist review.

  • New breathlessness or chest tightness

    Possible internal organ involvement - lungs, heart or diaphragm - needs same-day medical assessment.

  • Severe joint contracture

    Marked, worsening loss of joint movement risks permanent disability without prompt physiotherapy input.

  • Recent gadolinium exposure with reduced kidney function

    Anyone with an eGFR under 30 who has recently had gadolinium contrast should be monitored closely for early signs.

  • Acute kidney injury around the time of scanning

    A sudden drop in kidney function near the time of a gadolinium-enhanced scan raises the risk substantially.

  • Muscle weakness

    Fibrosis extending into skeletal muscle can cause weakness and reduced function needing specialist input.

  • Uncontrolled pain

    Pain that is not responding to standard analgesia should prompt a review of the overall management plan.

  • Diagnostic uncertainty

    Skin changes that do not fit a typical pattern deserve biopsy and specialist dermatology opinion rather than assumption.

Living with it

Managing day to day, with the right support.

Four things that make the biggest difference - staying mobile, protecting yourself from future exposure, managing discomfort and keeping specialist review in place.

A quiet reminder

Consistency in physiotherapy protects independence.

Small, steady movement habits - kept up over months - do more to preserve function than occasional bursts of activity.

  1. 01 Move

    Keep joints moving

    Daily stretching and physiotherapy-guided exercise help preserve mobility and slow further tightening.

  2. 02 Protect

    Avoid further gadolinium

    Make sure every future healthcare provider knows about your history before any MRI scan is booked.

  3. 03 Support

    Manage pain and skin discomfort

    A steady pain-management plan, plus gentle skin care, helps with day-to-day comfort.

  4. 04 Monitor

    Stay under specialist review

    Ongoing dermatology and nephrology follow-up helps catch any progression or organ involvement early.

Frequently asked

Everything we get asked about NSF.

Quick answers on risk, timing, diagnosis and prevention.

  • What is nephrogenic systemic fibrosis?

    A rare but serious condition causing thickening and hardening of the skin and connective tissue. It occurs almost exclusively in people with severe kidney impairment who have been exposed to certain gadolinium-based contrast agents used in MRI scans.

  • Who is at risk of developing it?

    The risk is concentrated in people with an eGFR under 30, acute kidney injury, or those on dialysis at the time of a gadolinium-enhanced MRI. People with normal or mildly reduced kidney function are not considered at meaningful risk.

  • How soon after a scan do symptoms appear?

    Symptoms typically develop days to months after gadolinium exposure. Onset can occasionally be delayed further, which is why a careful history of past scans matters when the diagnosis is being considered.

  • Is nephrogenic systemic fibrosis still common?

    No - it is now largely preventable. Since UK and EU protocols restricted the use of high-risk gadolinium agents in patients with significant renal impairment, new cases have become very uncommon.

  • Can it be cured?

    There is no definitive cure. Management is supportive - physiotherapy for joint mobility, pain control, treating any residual kidney impairment and avoiding further gadolinium exposure. Some severe cases have shown improvement with extracorporeal photopheresis under specialist care.

  • How is it diagnosed?

    Diagnosis combines a history of gadolinium exposure and kidney impairment with a skin biopsy for histological confirmation. Renal function is checked and a dermatology and nephrology referral is arranged for confirmed or suspected cases.

Related content

Keep reading.